glp-1 agonis Glucagon-like peptide-1 The Influence of Glucagon-like Peptide-1

Lee SH (2015) Intestinal permeability regulation by tight junction: Implication on inflammatory bowel diseases

The storage challenges described in this guide apply primarily to reconstituted liquid peptide preparations

Course Detail A comprehensive one-day course delivered in two parts, combining detailed theory with hands-on practical training in a clinical environment

Renal impairment GLP-1 RAs are generally safe in patients with CKD and have demonstrated nephroprotective effects in the FLOW trial, where semaglutide significantly reduced the composite renal endpoint (hospitalization for acute kidney injury, sustained 50% decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, or renal death) in patients with type 2 diabetes and CKD [15]